Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Category:Drug-metabolizing enzymes: Difference between revisions

Category page
Add Category:CuratedCategoryPage marker tag per interface-claude 2026-05-20. This marker lets MediaWiki:Common.css suppress MediaWiki's auto-generated 'Pages in category' list, which otherwise renders the member list a second time (machine-formatted) below the curated 'Enzymes indexed' section. Marker is the general non-MedCategory equivalent of the existing MedCategoryFull marker. No prose change.
Category:Drug-metabolizing enzymes: repoint the 11 enzyme links onto the Enzyme: namespace; correct the stale sandbox note (task #24)
 
Line 12: Line 12:


'''Cytochrome P450 (CYP) enzymes''', the hemoprotein monooxygenases responsible for the majority of phase-I oxidative drug metabolism:
'''Cytochrome P450 (CYP) enzymes''', the hemoprotein monooxygenases responsible for the majority of phase-I oxidative drug metabolism:
* [[Pharmacopedia:Pharmacogenomics sandbox/Enzyme CYP1A2|CYP1A2]] (caffeine probe; clozapine, olanzapine, theophylline, tizanidine; the tobacco-smoke induction story)
* [[Enzyme:CYP1A2|CYP1A2]] (caffeine probe; clozapine, olanzapine, theophylline, tizanidine; the tobacco-smoke induction story)
* [[Pharmacopedia:Pharmacogenomics sandbox/Enzyme CYP2B6|CYP2B6]] (efavirenz, methadone, bupropion, cyclophosphamide bioactivation)
* [[Enzyme:CYP2B6|CYP2B6]] (efavirenz, methadone, bupropion, cyclophosphamide bioactivation)
* [[Pharmacopedia:Pharmacogenomics sandbox/Enzyme CYP2C8|CYP2C8]] (paclitaxel, repaglinide, the glitazones; the gemfibrozil interaction)
* [[Enzyme:CYP2C8|CYP2C8]] (paclitaxel, repaglinide, the glitazones; the gemfibrozil interaction)
* [[Pharmacopedia:Pharmacogenomics sandbox/Enzyme CYP2C9|CYP2C9]] (warfarin, phenytoin, NSAIDs, sulfonylureas)
* [[Enzyme:CYP2C9|CYP2C9]] (warfarin, phenytoin, NSAIDs, sulfonylureas)
* [[Pharmacopedia:Pharmacogenomics sandbox/Enzyme CYP2C19|CYP2C19]] (clopidogrel, proton pump inhibitors, several SSRIs, voriconazole)
* [[Enzyme:CYP2C19|CYP2C19]] (clopidogrel, proton pump inhibitors, several SSRIs, voriconazole)
* [[Pharmacopedia:Pharmacogenomics sandbox/Enzyme CYP2D6|CYP2D6]] (codeine and tramadol activation, tricyclic antidepressants, many antipsychotics, metoprolol, tamoxifen)
* [[Enzyme:CYP2D6|CYP2D6]] (codeine and tramadol activation, tricyclic antidepressants, many antipsychotics, metoprolol, tamoxifen)
* [[Pharmacopedia:Pharmacogenomics sandbox/Enzyme CYP2E1|CYP2E1]] (ethanol, acetaminophen bioactivation, the halogenated anesthetics)
* [[Enzyme:CYP2E1|CYP2E1]] (ethanol, acetaminophen bioactivation, the halogenated anesthetics)
* [[Pharmacopedia:Pharmacogenomics sandbox/Enzyme CYP3A4|CYP3A4]] (the single most clinically consequential drug-metabolizing enzyme; roughly half of all medicines in clinical use)
* [[Enzyme:CYP3A4|CYP3A4]] (the single most clinically consequential drug-metabolizing enzyme; roughly half of all medicines in clinical use)


'''Phase-II and other non-CYP enzymes''':
'''Phase-II and other non-CYP enzymes''':
* [[Pharmacopedia:Pharmacogenomics sandbox/Enzyme UGT1A1|UGT1A1]] (UDP-glucuronosyltransferase; bilirubin, irinotecan, atazanavir)
* [[Enzyme:UGT1A1|UGT1A1]] (UDP-glucuronosyltransferase; bilirubin, irinotecan, atazanavir)
* [[Pharmacopedia:Pharmacogenomics sandbox/Enzyme TPMT|TPMT]] (thiopurine S-methyltransferase; azathioprine, mercaptopurine, thioguanine)
* [[Enzyme:TPMT|TPMT]] (thiopurine S-methyltransferase; azathioprine, mercaptopurine, thioguanine)
* [[Pharmacopedia:Pharmacogenomics sandbox/Enzyme NUDT15|NUDT15]] (nudix hydrolase; the parallel thiopurine-safety gene with a complementary ancestry distribution to TPMT)
* [[Enzyme:NUDT15|NUDT15]] (nudix hydrolase; the parallel thiopurine-safety gene with a complementary ancestry distribution to TPMT)


== Notes on scope ==
== Notes on scope ==
Line 32: Line 32:
Each enzyme page follows a common structure: a history-first opening, tissue distribution, the substrate spectrum with a sortable substrate table, phenotype categories, major genetic variants, inhibitors, inducers, clinical implications, and authoritative external resources. Each page is also the human-readable companion to the machine-level <code>pk_inhibit_via_&lt;ENZYME&gt;</code> and <code>pk_induce_via_&lt;ENZYME&gt;</code> interaction edges in the wiki's pharmacogenomic interaction layer.
Each enzyme page follows a common structure: a history-first opening, tissue distribution, the substrate spectrum with a sortable substrate table, phenotype categories, major genetic variants, inhibitors, inducers, clinical implications, and authoritative external resources. Each page is also the human-readable companion to the machine-level <code>pk_inhibit_via_&lt;ENZYME&gt;</code> and <code>pk_induce_via_&lt;ENZYME&gt;</code> interaction edges in the wiki's pharmacogenomic interaction layer.


These pages currently live as drafting sandboxes under the <code>Pharmacopedia:</code> project namespace (titled <code>Pharmacogenomics sandbox/Enzyme &lt;NAME&gt;</code>); their permanent home will be the dedicated <code>Enzyme:</code> namespace once it is registered. The closely related transporter, variant, and phenotype pages will live under <code>Transporter:</code>, <code>Variant:</code>, and <code>Phenotype:</code> respectively.
These pages live in the dedicated <code>Enzyme:</code> namespace. The closely related transporter, variant, and phenotype pages will live under <code>Transporter:</code>, <code>Variant:</code>, and <code>Phenotype:</code> respectively.


== References ==
== References ==